医師紹介

魚嶋 晴紀医師

非常勤医

魚嶋 晴紀HARUKI UOJIMA

専門分野肝臓 消化器病一般

2006年 旭川医科大学医学部卒業
2006年 茅ヶ崎徳洲会総合病院 初期臨床研修医
2008年 茅ヶ崎徳洲会総合病院 後期臨床研修医
2012年 湘南鎌倉総合病院 消化器内科
2014年 湘南鎌倉総合病院 消化器病センター 医長
2016年4月 北里大学 消化器内科 助教
2019年1月 北里大学 診療講師
2020年4月 北里大学 講師
2023年4月 国立国際医療研究センター

資格

  • 医学博士
  • 日本肝臓学会認定専門医・指導医
  • 日本内科学会総合内科専門医
  • 日本内科学会認定専門医
  • 日本消化器病学会認定消化器病専門医
  • 日本消化器内視鏡学会専門医
  • 日本臨床研修指導医
  • 神奈川県難病指定医

所属学会/その他

  • 日本肝臓学会
  • 日本内科学会
  • 日本消化器病学会
  • 日本消化器内視鏡学会
  • 日本腹部救急医学会
  • 日本門脈圧亢進症学会
  • 日本静脈経腸栄養学会
  • 日本血栓止血学会
  • 日本プライマリ・ケア連合学会
  • 日本臨床腸内微生物学会
  • 日本超音波医学会
  • 米国肝臓学会
  • 日本肝臓学会評議員
  • 日本肝臓学会 東部会評議員
  • 日本消化器病学会関東支部評議員
     
     

業績

【英文誌 原著】

  1. Uojima H, Kinbara T, Hidaka H, Sung JH, Ichida M, Tokoro S, Masuda S, Takizawa S, Sasaki A, Koizumi K, Egashira H, Kako M. Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites. Hepatol Res. 2017 Mar;47(3):E14-E21. doi: 10.1111/hepr.12716. Epub 2016 May 19. PMID: 27059410
  2. Uojima H, Kobayashi S, Hidaka H, Matsumoto S, Ohtake T, Kinbara T, Oka M, Yamanouchi Y, Kunieda T, Yamanoue H, Kanemaru T, Tsutsumi K, Fujikawa T, Sung Ji Hyun, Kako M. Virological response to daclatasvir and asunaprevir combination therapy for Chronic hepatitis C virus genotype 1b infection in dialysis patients: a prospective, multicenter study. Renal Replacement Therapy, 3: 7, 2017.
  3. Tanaka Y, Masaki T, Uojima H, Ohtake T, Fujikawa T, Yamanouchi T, Wada N, Kubota K, Hidaka H, Nakazawa T, Shibuya A, Aoyama T, Sung H, Kako M, Kobayashi S, Takeuchi Y and Koizumi W.Glecaprevir and pibrentasvir combination therapy for hepatitis C virus-infected Japanese patients on hemodialysis. Renal Replacement Therapy2018 4:51. https://doi.org/10.1186/s41100-018-0193-4
  4. Tanaka Y, Nakazawa T, Inoue T, Yamane K, Kubota K, Uojima H, Takada J, Okuwaki Y, Hidaka H, Shibuya A, Kokubu S, Matsunaga K, Koizumi W. Superparamagnetic iron oxide-enhanced magnetic resonance imaging is useful in predicting malignant potential of vascular transformation of hypointense hypovascular nodules on gadoxetic acid-enhanced magnetic resonance imaging. Hepatol Res. 2017 Oct;47(11):1118-1126. doi: 10.1111/hepr.12850. Epub 2017 Feb 21. PMID: 27943555
  5. Uojima H, Sakurai S, Hidaka H, Kinbara T, Sung JH, Ichita C, Tokoro S, Masuda S, Sasaki A, Koizumi K, Egashira H, Kako M, Kobayashi S. Effect of branched-chain amino acid supplements on muscle strength and muscle mass in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2017 Dec;29(12):1402-1407. doi: 10.1097/MEG.0000000000000968. PMID: 28984678
  6. Uojima H, Hidaka H, Nakayama T, Sung JH, Ichita C, Tokoro S, Masuda S, Sasaki A, Koizumi K, Egashira H, Kako M. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study. World J Gastroenterol. 2017 Dec 7;23(45):8062-8072. doi: 10.3748/wjg.v23.i45.8062. PMID: 29259382
  7. Toyoda H, Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, Fujioka S, Kondo C, Okubo T, Uojima H, Tada T, Yoneyama H, Watanabe T, Asano T, Ishikawa T, Tamai H, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Deguchi A, Itobayashi E, Mikami S, Moriya A, Okubo H, Tani J, Tsubota A, Tanaka Y, Masaki T, Iwakiri K, Kumada T. Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol. 2018 Dec;53(12):1276-1284. doi: 10.1007/s00535-018-1473-z. Epub 2018 May 8. PMID: 29740665
  8. Kubota K, Hidaka H, Nakazawa T, Okuwaki Y, Yamane K, Inoue T, Uojima H, Takada J, Tanaka Y, Shibuya A, Fujii K, Woodhams R, Matsunaga K, Kokubu S, Koizumi W. Prospective, randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma.Hepatol Res. 2018 Feb;48(3):E98-E106. doi: 10.1111/hepr.12933. Epub 2017 Jul 30. PMID: 28656607
  9. Uojima H, Hidaka H, Tanaka Y, Inoue T, Onoue M, Wada N, Kubota K, Nakazawa T, Shibuya A, Fujikawa T, Nakayama T, Yamanoue H, Sung JH, Kako M, Koizumi W. Wisteria floribunda agglutinin-positive human Mac-2 binding protein in decompensated cirrhosis. J Gastroenterol Hepatol. 2018 Nov;33(11):1889-1896. doi: 10.1111/jgh.14277. Epub 2018 May 29. PMID: 29737582
  10. Hiramine Y, Uojima H, Nakanishi H, Hiramatsu A, Iwamoto T, Kimura M, Kawaratani H, Terai S, Yoshiji H, Uto H, Sakaida I, Izumi N, Okita K, Koike K. Response criteria of tolvaptan for the treatment of hepatic edema. J Gastroenterol. 2018 Feb;53(2):258-268. doi: 10.1007/s00535-017-1366-6. Epub 2017 Jun 29.PMID: 28664229
  11. Uojima H, Arase Y, Itokawa N, Atsukawa M, Satoh T, Miyazaki K, Hidaka H, Sung JH, Kako M, Tsuruya K, Kagawa T, Iwakiri K, Horie R, Koizumi W. Relationship between response to lusutrombopag and splenic volume. World J Gastroenterol. 2018 Dec 14;24(46):5271-5279. doi: 10.3748/wjg.v24.i46.5271. PMID: 30581275
  12. Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Kondo C, Okubo T, Hiraoka A, Michitaka K, Fujioka S, Uojima H, Watanabe T, Ikeda H, Asano T, Ishikawa T, Matsumoto Y, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Mikami S, Tanaka Y, Kumada T, Iwakiri K. Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study. J Gastroenterol Hepatol. 2019 Feb;34(2):364-369. doi: 10.1111/jgh.14447. Epub 2018 Sep 14. PMID: 30144366
  13. Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, Fujioka S, Nakamuta M, Tada T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Yamashita N, Hiraoka A, Michitaka K, Shima T, Akahane T, Itobayashi E, Watanabe T, Ikeda H, Iio E, Fukunishi S, Asano T, Tachi Y, Ikegami T, Tsuji K, Abe H, Kato K, Mikami S, Okubo H, Shimada N, Ishikawa T, Matsumoto Y, Itokawa N, Arai T, Tsubota A, Iwakiri K, Tanaka Y, Kumada T. Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan. Open Forum Infect Dis. 2019 Apr 15;6(5):ofz185. doi: 10.1093/ofid/ofz185. eCollection 2019 May.PMID: 31123693
  14. Ikeda H, Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T. Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan. J Viral Hepat. 2019 Nov;26(11):1266-1275. doi: 10.1111/jvh.13170. Epub 2019 Aug 9.PMID: 31278795
  15. Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Aliment Pharmacol Ther. 2019 May;49(9):1230-1241. doi: 10.1111/apt.15218. Epub 2019 Mar 14. PMID: 30873651 Clinical Trial.
  16. Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Tada T, Tsutsui A, Ikeda H, Abe H, Kato K, Uojima H, Ikegami T, Asano T, Kondo C, Koeda M, Okubo T, Arai T, Iwashita-Nakagawa A, Itokawa N, Kumada T, Iwakiri K. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan. Hepatol Res. 2019 Apr;49(4):369-376. doi: 10.1111/hepr.13292. Epub 2019 Jan 2.
  17. Uojima H, Kobayashi S, Hidaka H, Kinbara T, Fujikawa T, Nakayama T, Yamanoue H, Kanemaru T, Hashimotoh T, Hyun Sung J, Kako M, Koizumi W. Efficacy and Tolerability of Ombitasvir/Paritaprevir/Ritonavir in HCV Genotype 1-infected Elderly Japanese Patients. Ann Hepatol. 2019 Jan-Feb;18(1):109-115. doi: 10.5604/01.3001.0012.7868.
  18. Sung JH, Uojima H, Hidaka H, Tanaka Y, Wada N, Kubota K, Nakazawa T, Shibuya A, Fujikawa T, Yamanoue H, Kako M, Koizumi W. Risk factors for loss of skeletal muscle mass in patients with cirrhosis. Hepatol Res. 2019 May;49(5):550-558. doi: 10.1111/hepr.13308. Epub 2019 Feb 1.
  19. Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Iwakiri K, Kumada T, Tanaka Y, Okanoue T. Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan. J Gastroenterol Hepatol. 2020 Aug;35(8):1420-1425. doi: 10.1111/jgh.14982. Epub 2020 Jan 31.
  20. Nozaki A, Atsukawa M, Kondo C, Toyoda H, Chuma M, Nakamuta M, Uojima H, Takaguchi K, Ikeda H, Watanabe T, Ogawa S, Itokawa N, Arai T, Hiraoka A, Asano T, Fujioka S, Ikegami T, Shima T, Ogawa C, Akahane T, Shimada N, Fukunishi S, Abe H, Tsubota A, Genda T, Okubo H, Mikami S, Morishita A, Moriya A, Tani J, Tachi Y, Hotta N, Ishikawa T, Okanoue T, Tanaka Y, Kumada T, Iwakiri K, Maeda S; KTK49 Liver Study Group.The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatol Int. 2020 Mar;14(2):225-238. doi: 10.1007/s12072-020-10019-z. Epub 2020 Mar 3.
  21. Ogushi K, Chuma M, Uojima H, Hidaka H, Numata K, Kobayashi S, Hirose S, Hattori N, Fujikawa T, Nakazawa T, Wada N, Iwasaki S, Fukushima T, Sano Y, Ueno M, Kawano K, Tsuruya K, Shomura M, Watanabe T, Matsunaga K, Kunishi Y, Saigusa Y, Irie K, Iwabuchi S, Kako M, Morimoto M, Kagawa T, Tanaka K, Maeda S.Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis. Clin Exp Gastroenterol. 2020 Oct 1;13:385-396. doi: 10.2147/CEG.S256691. eCollection 2020.
  22. Chuma M, Uojima H, Numata K, Hidaka H, Toyoda H, Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, Arai T, Kako M, Nakazawa T, Wada N, Iwasaki S, Miura Y, Hishiki S, Nishigori S, Morimoto M, Hattori N, Ogushi K, Nozaki A, Fukuda H, Kagawa T, Michitaka K, Kumada T, Maeda S. Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma.Cancers (Basel). 2020 Jan 26;12(2):293. doi: 10.3390/cancers12020293.
  23. Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asai A, Asano T, Ogawa C, Abe H, Hotta N, Shima T, Iio E, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Hidaka I, Moriya A, Tsuji K, Akahane T, Yamashita N, Okubo T, Arai T, Morita K, Kawata K, Tanaka Y, Okanoue T, Maeda S, Kumada T, Iwakiri K; KTK49 Liver Study Group. Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. Infect Dis Ther. 2020 Dec;9(4):851-866. doi: 10.1007/s40121-020-00329-y. Epub 2020 Sep 8.
  24. Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T. Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2020 May;35(5):855-861. doi: 10.1111/jgh.14874. Epub 2019 Nov 19.
  25. Sekine I, Uojima H, Koyama H, Kamio T, Sato M, Yamamoto T, Fukaguchi K, Fukui H, Yamagami H. Impact of non-pharmaceutical interventions for the COVID-19 pandemic on emergency department patient trends in Japan: a retrospective analysis. Acute Med Surg. 2020 Nov 28;7(1):e603. doi: 10.1002/ams2.603. eCollection 2020 Jan-Dec.PMID: 33282316
  26. Atsukawa M, Tsubota A, Takaguchi K, Toyoda H, Iwasa M, Ikegami T, Chuma M, Nozaki A, Uojima H, Hiraoka A, Fukunishi S, Yokohama K, Tada T, Kato K, Abe H, Tani J, Okubo H, Watanabe T, Hattori N, Tsutsui A, Senoh T, Yoshida Y, Okubo T, Itokawa N, Nakagawa-Iwashita A, Kondo C, Arai T, Michitaka K, Iio E, Kumada T, Tanaka Y, Takei Y, Iwakiri K. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. J Gastroenterol Hepatol. 2020 Jul;35(7):1229-1237. doi: 10.1111/jgh.14965. Epub 2020 Jan 14.
  27. Hidaka H, Tanabe S, Uojima H, Shao X, Iwasaki S, Wada N, Kubota K, Tanaka Y, Nakazawa T, Shibuya A, Kokubu S, Koizumi W. Long-term observation in patients with esophageal varices after endoscopic variceal ligation accompanied with 24-hour pH monitoring. Hepatol Res. 2020 Nov;50(11):1255-1263. doi: 10.1111/hepr.13562. Epub 2020 Sep 10. PMID: 32838474
  28. Hidaka H, Uojima H, Nakazawa T, Shao X, Hara Y, Iwasaki S, Wada N, Kubota K, Tanaka Y, Shibuya A, Kanoh Y, Kokubu S, Koizumi W. Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study. Hepatol Res. 2020 Sep;50(9):1083-1090. doi: 10.1111/hepr.13531. Epub 2020 Jul 27. PMID: 32515895
  29. Uojima H, Chuma M, Tanaka Y, Hidaka H, Nakazawa T, Iwabuchi S, Kobayashi S, Hattori N, Ogushi K, Morimoto M, Kagawa T, Tanaka K, Kako M, Koizumi W. Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer. 2020 Apr;9(2):193-206. doi: 10.1159/000504604. Epub 2019 Dec 6.
  30. Uojima H, Hidaka H, Tanaka Y, Wada N, Kubota K, Nakazawa T, Shibuya A, Sung JH, Kako M, Koizumi W. Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis. Dig Dis. 2020;38(1):38-45. doi: 10.1159/000501267. Epub 2019 Jun 19.
  31. Shao X, Uojima H, Setsu T, Okubo T, Atsukawa M, Furuichi Y, Arase Y, Hidaka H, Tanaka Y, Nakazawa T, Kako M, Kagawa T, Iwakiri K, Terai S, Koizumi W. Usefulness of autotaxin for the complications of liver cirrhosis. World J Gastroenterol. 2020 Jan 7;26(1):97-108. doi: 10.3748/wjg.v26.i1.97. PMID: 31933517
  32. Chuma M, Uojima H, Hattori N, Arase Y, Fukushima T, Hirose S, Kobayashi S, Ueno M, Tezuka S, Iwasaki S, Wada N, Kubota K, Tsuruya K, Shimma Y, Hiroki I, Takuya E, Tokoro C, Iwase S, Miura Y, Moriya S, Watanabe T, Hidaka H, Morimoto M, Numata K, Kusano C, Kagawa T, Maeda S. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. Hepatol Res. 2022 Mar;52(3):269-280. doi: 10.1111/hepr.13732. Epub 2021 Nov 30.
  33. Azuma S, Uojima H, Chuma M, Shao X, Hidaka H, Nakazawa T, Kondo M, Numata K, Iwabuchi S, Kako M, Maeda S, Koizumi W, Atsuda K. Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib. Sci Rep. 2020 Oct 13;10(1):17054. doi: 10.1038/s41598-020-73930-3.
  34. Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asano T, Ogawa C, Abe H, Kato K, Hotta N, Shima T, Matsuura K, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Morishita A, Hidaka I, Moriya A, Tsuji K, Akahane T, Okubo T, Arai T, Kitamura M, Morita K, Kawata K, Tanaka Y, Kumada T, Iwakiri K; KTK49 Liver Study Group.Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis. Hepatol Res. 2022 Mar;52(3):235-246. doi: 10.1111/hepr.13739. Epub 2021 Dec 17.
  35. Furuichi Y, Takeuchi H, Uojima H, Atsukawa M, Arai T, Arase Y, Kako M, Hidaka H, Itoi T. Lusutrombopag has slightly stronger effects on patients with mild thrombocytopenia compared with those with severe thrombocytopenia: A multicenter propensity score matching study. J Hepatobiliary Pancreat Sci. 2021 Dec 25. doi: 10.1002/jhbp.1099.
  36. Chuma M, Uojima H, Hiraoka A, Kobayashi S, Toyoda H, Tada T, Hidaka H, Iwabuchi S, Numata K, Itobayashi E, Itokawa N, Kariyama K, Ohama H, Hattori N, Hirose S, Shibata H, Tani J, Imai M, Tajiri K, Moriya S, Wada N, Iwasaki S, Fukushima T, Ueno M, Yasuda S, Atsukawa M, Nouso K, Fukunishi S, Watanabe T, Ishikawa T, Nakamura S, Morimoto M, Kagawa T, Sakamoto M, Kumada T, Maeda S. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. Hepatol Res. 2021 Feb;51(2):201-215. doi: 10.1111/hepr.13592. Epub 2021 Jan 5.PMID: 33270323
  37. Kikuchi N, Uojima H, Hidaka H, Iwasaki S, Wada N, Kubota K, Nakazawa T, Shibuya A, Fujikawa T, Kako M, Sato T, Koizumi W. Prospective study for an independent predictor of prognosis in liver cirrhosis based on the new sarcopenia criteria produced by the Japan Society of Hepatology. Hepatol Res. 2021 Sep;51(9):968-978. doi: 10.1111/hepr.13698. Epub 2021 Jul 31.
  38. Wada N, Uojima H, Satoh T, Okina S, Iwasaki S, Shao X, Takiguchi H, Arase Y, Itokawa N, Atsukawa M, Miyazaki K, Hidaka H, Kako M, Kagawa T, Iwakiri K, Horie R, Suzuki T, Koizumi W. Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.Dig Dis. 2021;39(3):234-242. doi: 10.1159/000510692. Epub 2020 Aug 6.
  39. Toyoda H, Leong J, Landis C, Atsukawa M, Watanabe T, Huang DQ, Liu J, Quek SXZ, Ishikawa T, Arai T, Yokohama K, Chuma M, Takaguchi K, Uojima H, Senoo T, Dang H, Maeda M, Hoang J, Le RH, Yasuda S, Thin KN, Tran S, Chien N, Henry L, Asai A, Fukunishi S, Cheung R, Lim SG, Trinh HN, Nguyen MH. Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice. Hepatology. 2021 Aug;74(2):656-666. doi: 10.1002/hep.31793. Epub 2021 May 22.
  40. Itokawa N, Atsukawa M, Tsubota A, Takaguchi K, Nakamuta M, Hiraoka A, Kato K, Abe H, Mikami S, Shimada N, Chuma M, Akito N, Uojima H, Ogawa C, Asano T, Tani J, Morishita A, Senoh T, Yamashita N, Oikawa T, Matsumoto Y, Koeda M, Yoshida Y, Tanabe T, Okubo T, Arai T, Hayama K, Iwashita AN, Kondo C, Tada T, Toyoda H, Kumada T, Iwakiri K. Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B. JGH Open. 2020 Nov 2;5(1):34-40. doi: 10.1002/jgh3.12443. eCollection 2021 Jan.
  41. Kawaratani H, Sawai H, Onishi M, Kogiso T, Shimada N, Uojima H, Nakajima T, Matsumoto N, Ikejima K, Ishikawa T, Terai S, Motoyama H, Komori A, Hirashima N, Saito S, Eguchi Y, Nojima M, Kawai Y, Tateyama M, Yoshiji H, Tanaka Y. A genome-wide association study identifying SVEP1 variant as a predictor of response to tolvaptan for cirrhotic ascites.Liver Int. 2021 Dec;41(12):2944-2953. doi: 10.1111/liv.15022. Epub 2021 Aug 8.
  42. Miyaaki H, Hiraoka A, Haraguchi M, Uojima H, Kawaratani H, Hiramatsu A, Hanai T, Hiasa Y, Yoshiji H, Okita K, Nakao K, Koike K. Proposal for new sleep disorder criteria in patients with chronic liver disease: Influence of liver-related complications. Hepatol Res. 2021 Nov 9. doi: 10.1111/hepr.13731.
  43. Kubota K, Uojima H, Shao X, Iwasaki S, Hidaka H, Wada N, Nakazawa T, Shibuya A, Kako M, Koizumi W. Additional L-carnitine Reduced the Risk of Hospitalization in Patients with Overt Hepatic Encephalopathy on Rifaximin. Dig Dis. 2021 Jun 28. doi: 10.1159/000518067.
  44. Shao X, Uojima H, Arai T, Ogawa Y, Setsu T, Atsukawa M, Furuichi Y, Arase Y, Horio K, Hidaka H, Nakazawa T, Kako M, Kagawa T, Iwakiri K, Nakajima A, Terai S, Tanaka Y, Koizumi W. The risk of cirrhosis and its complications based on PNPLA3 rs738409 G allele frequency. Dig Dis. 2021 Nov 22. doi: 10.1159/000521062.
  45. Masuda S, Koizumi K, Uojima H, Kimura K, Nishino T, Tasaki J, Ichita C, Sasaki A. Effect of Antibiotic Resistance of Pathogens on Initial Antibiotic Therapy for Patients With Cholangitis. Cureus. 2021 Oct 3;13(10):e18449. doi: 10.7759/cureus.18449. eCollection 2021 Oct.PMID: 34650837 Free PMC article.
  46. Toyoda H, Hiraoka A, Uojima H, Nozaki A, Shimada N, Takaguchi K, Abe H, Atsukawa M, Matsuura K, Ishikawa T, Mikami S, Watanabe T, Itobayashi E, Tsuji K, Arai T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Okubo T, Ehira T, Kumada T, Tanaka J. Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response. Hepatol Commun. 2021 May 5;5(7):1290-1299. doi: 10.1002/hep4.1716. eCollection 2021 Jul.PMID: 34278176 Free PMC article.
  47. Masuda S, Koizumi K, Nishino T, Tazawa T, Kimura K, Tasaki J, Ichita C, Sasaki A, Kako M, Uojima H, Sugitani A.Direct oral anticoagulants increase bleeding risk after endoscopic sphincterotomy: a retrospective study. BMC Gastroenterol. 2021 Oct 24;21(1):401. doi: 10.1186/s12876-021-01980-6.
  48. Arase Y, Matsumoto K, Anzai K, Tsuruya K, Sugiyama S, Yoshihara S, Hirose S, Uojima H, Hidaka H, Nakazawa T, Deguchi R, Kojima S, Takashimizu S, Shiraishi K, Shirai T, Kagawa T. Clinicopathological Features of Autoimmune Hepatitis with IgG4-Positive Plasma Cell Infiltration. Dig Dis. 2021;39(3):225-233. doi: 10.1159/000510562. Epub 2020 Jul 30.
  49. Hidaka H, Uojima H. Ultrasonography in the diagnosis of complications in patients with portal hypertension. J Med Ultrason (2001). 2021 Nov 17. doi: 10.1007/s10396-021-01158-3.
  50. Ogushi K,, Chuma M, Numata K, Nozaki A, Moriya S, Uojima H, Kondo M, Morimoto M, Maeda S. Impact of psoas muscle index assessed by a simple measurement method on tolerability and duration of continued treatment with sorafenib in hepatocellular carcinoma patients. Eur J Gastroenterol Hepatol. 2022 Jan 31. doi: 10.1097/MEG.0000000000002346. Online ahead of print.
  51. Fukushima T, Morimoto M, Ueno M, Kubota K, Uojima H, Hidaka H, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Yamamoto K, Tanaka K, Maeda S.Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting.JGH Open. 2021 Dec 17;6(1):29-35. doi: 10.1002/jgh3.12691. eCollection 2022 Jan.
  52. Kawata K, Atsukawa M, Ohta K, Chida T, Noritake H, Arai T, Iwakiri K, Yasuda S, Toyoda H, Okubo T, Hiraoka A, Watanabe T, Uojima H, Nozaki A, Tani J, Morishita A, Kageyama F, Sasada Y, Nagasawa M, Matsushita M, Oyaizu T, Mikami S, Ikegami T, Abe H, Matsuura K, Tanaka Y, Tsubota A. Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C.Hepatol Commun. 2022 Mar 28. doi: 10.1002/hep4.1941.
  53. Toyoda H, Yasuda S, Moriya A, Itobayashi E, Uojima H, Watanabe T, Atsukawa M, Arai T, Ishikawa T, Mikami S, Hiraoka A, Tsuji K, Oikawa T, Tsubota A, Nozaki A, Chuma M, Abe H, Shima T, Kumada T, Tanaka J. Misunderstanding of hepatitis C virus (HCV) infection status by non-specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy.J Infect Chemother. 2022 Sep;28(9):1231-1234. doi: 10.1016/j.jiac.2022.04.024. Epub 2022 May 6. PMID: 35534339
  54. Kikuchi N, Uojima H, Hidaka H, Iwasaki S, Wada N, Kubota K, Nakazawa T, Shibuya A, Kako M, Také A, Sakaguchi Y, Sato T, Kusano C. Evaluation of skeletal muscle mass in patients with chronic liver disease shows different results based on bioelectric impedance analysis and computed tomography.Ann Nutr Metab. 2022 Aug 18. doi: 10.1159/000526563. PMID: 35981519
  55. Kobayashi S, Fukushima T, Ueno M, Moriya S, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Suzuki M, Uojima H, Hidaka H, Kusano C, Suzuki M, Morimoto M. A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma. BMC Cancer. 2022 May 7;22(1):517. doi: 10.1186/s12885-022-09625-x. PMID: 35525913
  56. Hayama K, Atsukawa M, Tsubota A, Kondo C, Iwasa M, Hasegawa H, Takaguchi K, Tsutsui A, Uojima H, Hidaka H, Okubo H, Suzuki T, Matsuura K, Tada T, Kawabe N, Tani J, Morishita A, Ishikawa T, Arase Y, Furuichi Y, Kato K, Kawata K, Chuma M, Nozaki A, Hiraoka A, Watanabe T, Kagawa T, Toyoda H, Taniai N, Yoshida H, Tanaka Y, Iwakiri K; KTK49 Liver Study Group. Clinical outcomes of antithrombin III-based therapy for patients with portal vein thrombosis: A retrospective, multicenter study. Hepatol Res. 2022 Sep 22. doi: 10.1111/hepr.13840. Online ahead of print. PMID: 36136893
  57. Shiha G, Soliman R, Mikhail NNH, Carrat F, Azzi J, Nathalie GC, Toyoda H, Uojima H, Nozaki A, Takaguchi K, Hiraoka A, Atsukawa M, Abe H, Matsuura K, Mikami S, Watanabe T, Tsuji K, Ishikawa T, Suri V, Osinusi A, Ni L, Zou J, Sarin SK, Kumar M, Jalal PK, Hashim MA, Hassan M, Lopez SA, Bañares R, Ahumada AM, Mousa NH, Eslam M, Waked I. International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients. J Viral Hepat. 2022 Sep;29(9):807-816. doi: 10.1111/jvh.13717. Epub 2022 Jun 24. PMID: 35657138
  58. Kawamura A, Uojima H, Chuma M, Shao X, Hidaka H, Nakazawa T, Take A, Sakaguchi Y, Numata K, Kako M, Nozaki A, Azuma S, Horio K, Kusano C, Atsuda K. The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma. BMC Cancer. 2022 Aug 23;22(1):912. doi: 10.1186/s12885-022-10002-x. PMID: 35999529
  59. Chuma M, Yokoo H, Hiraoka A, Ueda K, Yokoyama T, Tsuji K, Shimada N, Uojima H, Kobayashi S, Hattori N, Okubo T, Atsukawa M, Ishikawa T, Takaguchi K, Tsutsui A, Toyoda H, Tada T, Saito Y, Hirose S, Tanaka T, Takeda K, Otani M, Sekikawa Z, Watanabe T, Hidaka H, Morimoto M, Numata K, Kagawa T, Sakamoto M, Kumada T, Maeda S. Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment. Curr Oncol. 2022 May 4;29(5):3259-3271. doi: 10.3390/curroncol290 50266. PMID: 35621656
  60. Satoh T, Takiguchi H, Uojima H, Kubo M, Tanaka C, Yokoyama F, Wada N, Miyazaki K, Hidaka H, Kusano C, Kuwana M, Horie R. B cell-activating factor is involved in thrombocytopenia in patients with liver cirrhosis. Ann Hematol. 2022 Nov;101(11):2433-2444. doi: 10.1007/s00277-022-04973-x. Epub 2022 Sep 13. PMID: 36098792
  61. Masuda S, Tsukiyama T, Minagawa Y, Koizumi K, Kako M, Kinbara T, Uojima H. Hepatocellular carcinoma effective stereotactic body radiotherapy using Gold Anchor and the Synchrony system: Two case reports and review of literature. World J Clin Cases. 2022 Mar 16;10(8):2591-2603. doi: 10.12998/wjcc.v10.i8.2591. PMID: 35434047
  62. Arai T, Atsukawa M, Tsubota A, Mikami S, Uojima H, Yoshikata K, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol Commun. 2022 Nov;6(11):3073-3082. doi: 10.1002/hep4.2069. Epub 2022 Aug 30. PMID: 36039537
  63. Masuda S, Koizumi K, Shionoya K, Jinushi R, Makazu M, Nishino T, Kimura K, Sumida C, Kubota J, Ichita C, Sasaki A, Kobayashi M, Kako M, Haruki U. Comprehensive review on small common bile duct stones. World J Gastroenterol. 2023 Apr 7;29(13):1955-1968. doi: 10.3748/wjg.v29.i13.1955.
  64. Atsukawa M, Tsubota A, Kondo C, Koyano KS, Ishikawa T, Toyoda H, Takaguchi K, Watanabe T, Matsuura K, Ogawa C, Hiraoka A, Okubo H, Tateyama M, Uojima H, Nozaki A, Chuma M, Kato K, Mikami S, Tani J, Morishita A, Kawata K, Tada T, Furuichi Y, Okubo T, Kawano T, Arai T, Kawabe N, Kawamura N, Ikegami T, Nakamuta M, Shigefuku R, Iwasa M, Tanaka Y, Hatano M, Iwakiri K. Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study. Hepatol Int. 2023 Feb;17(1):139-149. doi: 10.1007/s12072-022-10456-y. Epub 2022 Dec 7.
  65. Masuda S, Koizumi K, Shionoya K, Jinushi R, Makazu M, Nishino T, Kimura K, Sumida C, Kubota J, Ichita C, Sasaki A, Kobayashi M, Kako M, Haruki U. Comprehensive review on endoscopic ultrasound-guided tissue acquisition techniques for solid pancreatic tumor. World J Gastroenterol. 2023 Mar 28;29(12):1863-1874. doi: 10.3748/wjg.v29.i12.1863.
  66. Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, Dai CY, Ogawa E, Ishigami M, Ito T, Kozuka R, Enomoto M, Suzuki T, Yoshimaru Y, Preda CM, Marin RI, Sandra I, Tran S, Quek SXZ, Khine HHTW, Itokawa N, Atsukawa M, Uojima H, Watanabe T, Takahashi H, Inoue K, Maeda M, Hoang JK, Trinh L, Barnett S, Cheung R, Lim SG, Trinh HN, Chuang WL, Tanaka Y, Toyoda H, Yu ML, Nguyen MH. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase. Hepatology. 2023 May 16. doi: 10.1097/HEP.0000000000000459. Online ahead of print.
  67. Masuda S, Tsukiyama T, Makazu M, Jinushi R, Koizumi K, Nishino T, Shionoya K, Kimura K, Sumida C, Kubota J, Ichita C, Sasaki A, Kobayashi M, Kako M, Uojima H. A case of unsuccessful obliteration of percutaneous transhepatic gastric varices using the IMPEDE embolization plug. Clin Case Rep. 2023 May 9;11(5):e07323. doi: 10.1002/ccr3.7323. eCollection 2023 May.
  1. Uojima H, Chuma M, Hidaka H, Tsuda T, Kobayashi S, Hattori N, Ogushi K, Arase Y, Take A, Sakaguchi Y, Tomoko A, Nishigori S, Wanatanbe T, Numata K, Morimoto M, Kagawa T, Kako M, Kusano C. Impact of body composition for patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab therapy. Eur J Gastroenterol Hepatol. 2023 Aug 1;35(8):865-873. doi: 10.1097/MEG.0000000000002581. Epub 2023 Jun 6.
  2. Toyoda H, Kanneganti M, Melendez-Torres J, Parikh ND, Jalal PK, Piñero F, Mendizabal M, Ridruejo E, Cheinquer H, Casadei-Gardini A, Weinmann A, Peck-Radosavljevic M, Dufour JF, Radu P, Shiha G, Soliman R, Sarin SK, Kumar M, Wang JH, Tangkijvanich P, Sukeepaisarnjaroen W, Atsukawa M, Uojima H, Nozaki A, Nakamuta M, Takaguchi K, Hiraoka A, Abe H, Matsuura K, Watanabe T, Shimada N, Tsuji K, Ishikawa T, Mikami S, Itobayashi E, Singal AG, Johnson PJ. Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2023 Jul 11:S1542-3565(23)00534-7. doi: 10.1016/j.cgh.2023.06.026. Online ahead of print.
  3. Wong YJ, Tran S, Huang CF, Hsu YC, Preda C, Toyoda H, Liu J, Jun DW, Landis C, Huang DQ, Gila A, Negoita L, Yasuda S, Tseng CH, Tsai PC, Uojima H, Nozaki A, Chuma M, Atsukawa M, Ishigami M, Itokawa N, Iio E, Lam CP, Watanabe T, Asai A, Yokohama K, Abe H, Enomoto M, Kawada N, Tamori A, Lee DH, Jun MJ, Do S, Vo DKH, Liu L, Li J, Ji F, Wang W, Li Y, Wang X, Guo F, Xu Q, Jing L, Ye Q, Pan H, Zhang J, Wen X, Wang Q, Ren H, Cai D, Shang J, Liu J, Lu C, Zang W, Li J, Niu J, Zhang M, Wu C, Huang R, Maeda M, Nakanishi A, Yeh ML, Chuang WL, Huang JF, Dai C, Ishikawa T, Takaguchi K, Senoh T, Trinh HN, Takahashi H, Eguchi Y, Quek SXZ, Haga H, Ogawa E, Wong G, Buti M, Fukunishi S, Ueno Y, Yuen MF, Tanaka Y, Lim SG, Cheung R, Yu ML, Nguyen MH. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study. Hepatol Int. 2023 Jun 5. doi: 10.1007/s12072-023-10547-4. Online ahead of print.
  4. Masuda S, Jinushi R, Koizumi K, Makazu M, Nishino T, Shionoya K, Kimura K, Sumida C, Kubota J, Ichita C, Sasaki A, Kobayashi M, Kako M, Uojima H, Sugitani A. Endoscopic Papillary Balloon Dilation Can Be Safely Performed in Patients on Dual Antiplatelet Therapy: A Pilot Study. J Gastrointestin Liver Dis. 2023 Jun 22;32(2):216-221. doi: 10.15403/jgld-4764.
  1. Fukushima T, Morimoto M, Kobayashi S, Ueno M, Uojima H, Hidaka H, Kusano C, Chuma M, Numata K, Tsuruya K, Arase Y, Kagawa T, Hattori N, Ikeda H, Watanabe T, Tanaka K, Maeda S. Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. Oncologist. 2023 Jul 5;28(7):e526-e533. doi: 10.1093/oncolo/oyad090.
  2. Také A, Uojima H, Sakaguchi Y, Gotoh K, Satoh T, Hidaka H, Horio K, Mizokami M, Hayashi S, Kusano C. Impact of liver fibrosis on the relative abundance of a urease-positive Streptococcus salivarius group from saliva in patients with chronic liver disease. Hepatol Res. 2023 Jun 6. doi: 10.1111/hepr.13930. Online ahead of print.
  3. Satoh T, Uojima H, Wada N, Takiguchi H, Kaneko M, Nakamura M, Gonda N, Homma M, Hidaka H, Kusano C, Horie R. Introduction of direct-acting antiviral agents alters frequencies of anti-GPIIb/IIIa antibody-producing B cells in chronic hepatitis C patients with thrombocytopenia.Platelets. 2023 Dec;34(1):2161498. doi:10.1080/09537104.2022.2161498.
  1. Hayama K, Atsukawa M, Tsubota A, Kondo C, Iwasa M, Hasegawa H, Takaguchi K, Tsutsui A, Uojima H, Hidaka H, Okubo H, Suzuki T, Matsuura K, Tada T, Kawabe N, Tani J, Morishita A, Ishikawa T, Arase Y, Furuichi Y, Kato K, Kawata K, Chuma M, Nozaki A, Hiraoka A, Watanabe T, Kagawa T, Toyoda H, Taniai N, Yoshida H, Tanaka Y, Iwakiri K; KTK49 Liver Study Group. Clinical outcomes of antithrombin III-based therapy for patients with portal vein thrombosis: A retrospective, multicenter study. Hepatol Res. 2023 Jan;53(1):51-60. doi: 10.1111/hepr.13840. Epub 2022 Oct 4.
  1. Arai T, Atsukawa M, Tsubota A, Mikami S, Haruki U, Yoshikata K, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol Commun.   2022 Nov;6(11):3073-3082. doi: 10.1002/hep4.2069. Epub 2022 Aug 30.
  1. Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, Dai CY, Ogawa E, Ishigami M, Ito T, Kozuka R, Enomoto M, Suzuki T, Yoshimaru Y, Preda CM, Marin RI, Sandra I, Tran S, Quek SXZ, Khine HHTW, Itokawa N, Atsukawa M, Uojima H, Watanabe T, Takahashi H, Inoue K,  Maeda M, Hoang JK, Trinh L, Barnett S, Cheung R, Lim SG, Trinh HN, Chuang WL, Tanaka Y, Toyoda H, Yu ML, Nguyen MH. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase. Hepatology. 2023 Nov 1;78(5):1558-1568. doi: 10.1097/HEP.0000000000000459. Epub 2023 May 16. Masuda S, Koizumi K, Shionoya K, Jinushi R, Makazu M, Nishino T, Kimura K, Sumida C,  Kubota J, Ichita C, Sasaki A, Kobayashi M, Kako M, Haruki U. Comprehensive review on  endoscopic ultrasound-guided tissue acquisition techniques for solid pancreatic tumor.  World J Gastroenterol. 2023 Mar 28;29(12):1863-1874. doi: 10.3748/wjg.v29.i12.1863.  PMID: 37032729 Free PMC article. Review.
  1. Uojima H, Sakaguchi Y, Gotoh K, Satoh T, Hidaka H, Take A, Horio K, Hayashi S, Kusano C.  Metabolic dysfunction-associated fatty liver disease on distinct microbial communities at the  bacterial phylum level. Dig Dis. 2023 Sep 28. doi:10.1159/000534284. Online ahead of print.  PMID: 37769624 Free article.
  1. Uojima H, Chuma M, Hidaka H, Tsuda T, Kobayashi S, Hattori N, Ogushi K, Arase Y, Take A,  Sakaguchi Y, Tomoko A, Nishigori S, Wanatanbe T, Numata K, Morimoto M, Kagawa T, Kako M, Kusano C. Impact of body composition for patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab therapy. Eur J Gastroenterol Hepatol. 2023 Aug 1;35(8):865-873. doi: 10.1097/MEG.0000000000002581. Epub 2023 Jun 6. PMID: 37395239
  1. Wong YJ, Tran S, Huang CF, Hsu YC, Preda C, Toyoda H, Liu J, Jun DW, Landis C, Huang DQ, Gila A, Negoita L, Yasuda S, Tseng CH, Tsai PC, Uojima H, Nozaki A, Chuma M, Atsukawa M, Ishigami M, Itokawa N, Iio E, Lam CP, Watanabe T, Asai A, Yokohama K, Abe H, Enomoto M, Kawada N, Tamori A, Lee DH, Jun MJ, Do S, Vo DKH, Liu L, Li J, Ji F, Wang W, Li Y, Wang X, Guo F, Xu Q, Jing L, Ye Q, Pan H, Zhang J, Wen X, Wang Q, Ren H, Cai D, Shang J, Liu J, Lu C, Zang W, Li J, Niu J, Zhang M, Wu C, Huang R, Maeda M, Nakanishi A, Yeh ML, Chuang WL, Huang JF, Dai C, Ishikawa T, Takaguchi K, Senoh T, Trinh HN, Takahashi H, Eguchi Y, Quek SXZ, Haga H, Ogawa E, Wong G, Buti M, Fukunishi S, Ueno Y, Yuen MF, Tanaka Y, Lim SG, Cheung R, Yu ML, Nguyen MH. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study. Hepatol Int. 2023Oct;17(5):1150-1161. doi: 10.1007/s12072-023-10547-4. Epub 2023 Jun 5.
  2. Chau A, Yeh ML, Tsai PC, Huang DQ, Kim SE, Trinh H, Yoon EL, Oh H, Jeong JY, Ahn SB, An J, Tseng CH, Hsu YC, Jeong SW, Cho YK, Shim JJ, Kim HS, Ito T, Marciano S, Kawashima K, Suzuki T, Watanabe T, Nozaki A, Ishikawa T, Inoue K, Eguchi Y, Uojima H, Abe H, Takahashi H, Chuma M, Ishigami M, Hoang JK, Mayumi M, Huang CF, Gadano A, Dai CY, Huang JF, Tanaka Y, Chuang WL, Lim SG, Cheung R, Yu ML, Jun DW, Nguyen MH. Sex Differences in Treatment Response to Nucleos(t)ide Therapy in Chronic Hepatitis B: A Multicenter Longitudinal Study. Clin Gastroenterol Hepatol. 2023 Sep 19:S1542-3565(23)00713-9. doi: 10.1016/j.cgh.2023.09.002. Online ahead of print. PMID: 37734582
  1. Masuda S, Jinushi R, Koizumi K, Makazu M, Nishino T, Shionoya K, Kimura K, Sumida C,

      Kubota J, Ichita C, Sasaki A, Kobayashi M, Kako M, Uojima H, Sugitani A. Endoscopic            Papillary Balloon Dilation Can Be Safely Performed in Patients on Dual Antiplatelet                Therapy: A Pilot Study.   J Gastrointestin Liver Dis. 2023 Jun 22;32(2):216-221.                          doi: 10.15403/jgld-4764.

  1. Fukushima T, Morimoto M, Kobayashi S, Ueno M, Uojima H, Hidaka H, Kusano C, Chuma M, Numata K, Tsuruya K, Arase Y, Kagawa T, Hattori N, Ikeda H, Watanabe T, Tanaka K, Maeda S. Association Between Immune-Related Adverse Events and Survival in Patients with  Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. Oncologist. 2023 Jul 5;28(7):e526-e533. doi: 10.1093/oncolo/oyad090. PMID: 37023703 Free PMC article.
  1. 85. Uojima H, Nakabayashi K, Yamasaki K, Sugiyama M, Ishii N, Shirabe K, Kyoutou T, Ueda K, Takahama Y, Tamaki N, Kurosaki M, Hidaka H, Kusano C, Amano K, Kawaguchi T, Taketomi  A, Joshita S, Umemura T, Murakawa M, Asahina Y, Suzuki T, Matsuura K, Nishimura T, Iijima  H, Sakamoto K, Ito K, Nishina S, Hino K, Toyoda H, Yatsuhashi H, Kage M, Mizokami M.  New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding  protein glycosylation isomer in chronic liver disease. J Gastroenterol. 2023 Oct 8. doi: 10.1007/s00535-023-02043-1. Online ahead of print. PMID: 37812281
  1. Také A, Uojima H, Sakaguchi Y, Gotoh K, Satoh T, Hidaka H, Horio K, Mizokami M, Hayashi S, Kusano C. Impact of liver fibrosis on the relative abundance of a urease-positive Streptococcus salivarius group from saliva in patients with chronic liver disease. Hepatol Res. 2023 Oct;53(10):998-1007. doi: 10.1111/hepr.13930. Epub 2023 Jun 19. PMID: 37279155
  2. Jang TY, Liang PC, Jun DW, Jung JH, Toyoda H, Wang CW, Yuen MF, Cheung KS, Yasuda S, Kim SE, Yoon EL, An J, Enomoto M, Kozuka R, Chuma M, Nozaki A, Ishikawa T, Watanabe T,    Atsukawa M, Arai T, Hayama K, Ishigami M, Cho YK, Ogawa E, Kim HS, Shim JJ, Uojima H, Jeong SW, Ahn SB, Takaguchi K, Senoh T, Buti M, Vargas-Accarino E, Abe H, Takahashi H, Inoue K, Huang JF, Chuang WL, Yeh ML, Dai CY, Huang CF, Nguyen MH, Yu ML. Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs. Kaohsiung J Med Sci. 2023 Oct 27. doi: 10.1002/kjm2.12771.  Online ahead of print. PMID: 37885338 Free article.
  3. New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease.Uojima H, Nakabayashi K, Yamasaki K, Sugiyama M, Ishii N, Shirabe K, Kyoutou T, Ueda K, Takahama Y, Tamaki N, Kurosaki M, Hidaka H, Kusano C, Amano K, Kawaguchi T, Taketomi A, Joshita S, Umemura T, Murakawa M, Asahina Y, Suzuki T, Matsuura K, Nishimura T, Iijima H, Sakamoto K, Ito K, Nishina S, Hino K, Toyoda H, Yatsuhashi H, Kage M, Mizokami M.J Gastroenterol. 2023 Dec;58(12):1252-1260. doi: 10.1007/s00535-023-02043-1. Epub 2023 Oct 8.PMID: 37812281
  4.  Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs.Jang TY, Liang PC, Jun DW, Jung JH, Toyoda H, Wang CW, Yuen MF, Cheung KS, Yasuda S, Kim SE, Yoon EL, An J, Enomoto M, Kozuka R, Chuma M, Nozaki A, Ishikawa T, Watanabe T, Atsukawa M, Arai T, Hayama K, Ishigami M, Cho YK, Ogawa E, Kim HS, Shim JJ, Uojima H, Jeong SW, Ahn SB, Takaguchi K, Senoh T, Buti M, Vargas-Accarino E, Abe H, Takahashi H, Inoue K, Huang JF, Chuang WL, Yeh ML, Dai CY, Huang CF, Nguyen MH, Yu ML.Kaohsiung J Med Sci. 2024 Feb;40(2):188-197. doi: 10.1002/kjm2.12771. Epub 2023 Oct 27.PMID: 37885338 Free article.
  5.  Exploration of predictors associated with bleeding in computed tomography-guided core needle splenic biopsy: A retrospective study.Masuda S, Tsukiyama T, Daigo R, Makazu M, Jinushi R, Koizumi K, Nishino T, Shionoya K, Kimura K, Sumida C, Kubota J, Ichita C, Sasaki A, Kobayashi M, KakoM,UojimaH.Medicine (Baltimore). 2023 Nov 17;102(46):e34951. doi:10.1097/MD.0000000000034951.PMID: 37986279 Free PMC article.
  6.  Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response.Park JE, Nguyen VH, Tsai PC, Toyoda H, Leong J, Guy JE, Yeh ML, Huang CF, Yasuda S, Abe H, Hsu YC, Tseng CH, Liu J, Chen YL, Lin PY, Jun DW, Yoshimaru Y, Ogawa E, Ishigami M, Enomoto M, Tamori A, Uojima H, Wang XZ, Xu Q, Takahashi H, Eguchi Y, Inoue K, Huang DQ, Zhao WJ, Chuang WL, Dai CY, Huang JF, Barnett S, Maeda M, Cheung R, Landis C, Tanaka Y, Roberts LR, Schwartz ME, Kumada T, Yu ML, Nguyen MH.Aliment Pharmacol Ther. 2024 Mar;59(6):742-751. doi: 10.1111/apt.17863. Epub 2024 Jan 3.PMID: 38173278
  7.  Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma.Huang DQ, Hoang JK, Kamal R, Tsai PC, Toyoda H, Yeh ML, Yasuda S, Leong J, Maeda M, Huang CF, Won Jun D, Ishigami M, Tanaka Y, Uojima H, Ogawa E, Abe H, Hsu YC, Tseng CH, Alsudaney M, Yang JD, Yoshimaru Y, Suzuki T, Liu JK, Landis C, Dai CY, Huang JF, Chuang WL, Schwartz M, Dan YY, Esquivel C, Bonham A, Yu ML, Nguyen MH.J Clin Oncol. 2024 Mar 1;42(7):790-799. doi: 10.1200/JCO.23.00757. Epub 2024 Jan 4.PMID: 38175991
  8.  Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.Toyoda H, Tada T, Uojima H, Nozaki A, Chuma M, Takaguchi K, Hiraoka A, Abe H, Itobayashi E, Matsuura K, Atsukawa M, Watanabe T, Shimada N, Nakamuta M, Kojima M, Tsuji K, Mikami S, Ishikawa T, Yasuda S, Tsutsui A, Arai T, Kumada T, Tanaka Y, Tanaka J, Chayama K.J Gastroenterol Hepatol. 2024 Jan 30. doi: 10.1111/jgh.16494. Online ahead of print.PMID: 38291715
  9.  Effectiveness of antibiotic prophylaxis for acute esophageal variceal bleeding in patients with band ligation: A large observational study.Ichita C, Shimizu S, Goto T, Haruki U, Itoh N, Iwagami M, Sasaki A.World J Gastroenterol. 2024 Jan 21;30(3):238-251. doi: 10.3748/wjg.v30.i3.238.PMID: 38314133 Free PMC article.
  10.  Potential of Mac-2-binding protein glycan isomer as a new therapeutic target in pancreatic cancer.Yamanaka T, Araki K, Yokobori T, Muranushi R, Hoshino K, Hagiwara K, Gantumur D, Ishii N, Tsukagoshi M, Watanabe A, Harimoto N, Masamune A, Uojima H, Mizokami M, Ito K, Shirabe K.Cancer Sci. 2024 Feb 6. doi: 10.1111/cas.16087. Online ahead of print.PMID: 38321872 Free article.
  11.  Association of short-course antimicrobial therapy and bacterial resistance in acute cholangitis: Retrospective cohort study.Masuda S, Jinushi R, Imamura Y, Kubota J, Kimura K, Shionoya K, Makazu M, Sato R, Kako M, Kobayashi M, Uojima H, Koizumi K. Endosc Int Open. 2024 Feb 28;12(2):E307-E316. doi: 10.1055/a-2230-8229. eCollection 2024 Feb. PMID: 38420157 Free PMC article.
  12.  Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.Kobayashi S, Fukushima T, Ueno M, Chuma M, Numata K, Tsuruya K, Arase Y, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Uojima H, Hidaka H, Kusano C, Morimoto M, Maeda S.Liver Int. 2024 Mar 4. doi: 10.1111/liv.15825. Online ahead of print.PMID: 38436529
  13. Development and validation of a scoring system for in-hospital mortality following band ligation in esophageal variceal bleeding.Ichita C, Goto T, Okada Y, Uojima H, Iwagami M, Sasaki A, Shimizu S.Dig Endosc. 2024 Mar 11. doi: 10.1111/den.14773. Online ahead of print. PMID: 38462957
  14.  Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study.Jang TY, Liang PC, Jun DW, Jung JH, Toyoda H, Wang CW, Yuen MF, Cheung KS, Yasuda S, Kim SE, Yoon EL, An J, Enomoto M, Kozuka R, Chuma M, Nozaki A, Ishikawa T, Watanabe T, Atsukawa M, Arai T, Hayama K, Ishigami M, Cho YK, Ogawa E, Kim HS, Shim JJ, Uojima H, Jeong SW, Ahn SB, Takaguchi K, Senoh T, Buti M, Vargas-Accarino I E, Abe H, Takahashi H, Inoue K, Yeh ML, Dai CY, Huang JF, Huang CF, Chuang WL, Nguyen MH, Yu ML. J Gastroenterol Hepatol. 2024 Mar 13. doi: 10.1111/jgh.16537. Online ahead of print. PMID: 38480009
  15.  Antimicrobial therapy outcomes in acute cholangitis: Hilar multiple obstructions versus single hilar and common bile duct obstructions.

      Masuda S, Imamura Y, Jinushi R, Kubota J, Kimura K, Makazu M, Sato R, Kako M,                    Kobayashi M, Uojima H, Ichita C, Koizumi K. JGH Open. 2024 Mar 14;8(3):e13047. doi:            10.1002/jgh3.13047. eCollection 2024 Mar. PMID: 38486876 Free PMC article.

【招待講演・学会発表・特許など】

  1. 魚嶋 晴紀 日高 央 アルコール性肝障害に対するHarm reduction導入後のdrinking risk levelの変化と治療効果に関する検討 第57回日本肝臓学会総会(ワークショップ)
  2. 魚嶋 晴紀 日高 央 井廻 佳菜  PNPLA3遺伝子多型が肝硬変合併症発生に与える影響 第57回日本肝臓学会総会 札幌 (パネルディスカッション)
  3. 魚嶋 晴紀 日高 央  肝サルコペニア診断基準の有用性に関する多施設前向き検討 第57回日本肝臓学会総会 (パネルディスカッション)
  4. 魚嶋 晴紀 日高 央 岩崎秀一郎 治療適応消化管静脈瘤の予測因子としてのアルブミン・ビリルビン・血小板値(ABP criteria)の有用性  第57回日本肝臓学会総会 (シンポジウム)
  5. 魚嶋 晴紀 日高 央  アルコール性肝硬変患者に対するナルメフェンの有用性 第43回日本肝臓学会東部会 (シンポジウム)
  6. 魚嶋 晴紀 日高 央  代償性肝硬変から非代償性肝硬変における治療介入のタイミングと治療抵抗因子第43回日本肝臓学会東部会 (教育プログラム:招待講演)
  7. 魚嶋 晴紀 抗GPIIb/IIIa抗体産生B細胞数がトロンボポエチン受容体アゴニスト投与後の治療効果に与える影響 第27回日本門脈圧亢進症学会 (シンポジウム)
  8. 魚嶋 晴紀 肝性脳症に対するレボカルニチン+リファキシミン併用療法がサルコペニアに与える影響 第27回日本門脈圧亢進症学会(シンポジウム)
  9. 魚嶋 晴紀 慢性肝疾患におけるサルコペニアとたんぱく質摂取量に関する検討 第27回日本門脈圧亢進症学会(ワークショップ)
  10. 魚嶋 晴紀 消化管静脈瘤破裂予測因子としてのアルブミン・ビリルビン・血小板値(ABP criteria)の有用性 第27回日本門脈圧亢進症学会 福岡 11,2020.(ワークショップ)
  11. 魚嶋 晴紀 日高 央 賀古 眞 肝性脳症に対するレボカルニチン+リファキシミン併用療法に関するランダム並行群間比較試験 第28回日本消化器関連学会週間(JDDW 2020)(パネルディスカッション)
  12. 魚嶋 晴紀 日髙 央 賀古 眞 慢性肝障害を合併するアルコール依存症患者に対するナルメフェン投与に関する前向き検討 第56回日本肝臓学会(ワークショップ)
  13. 魚嶋 晴紀 日髙 央 賀古 眞 慢性肝疾患に続発した二次性免疫性血小板減少症に対するトロンボポエチン受容体アゴニストの有用性 第56回日本肝臓学会(パネルディスカッション)
  14. 肝線維化進展におけるAutotaxinの変化に関する検討 魚嶋 晴紀 日高 央 賀古 眞 第27回日本消化器関連学会週間(JDDW 2019) (ワークショップ)
  15. Clinical Usefulness of Autotaxin in Patients with Liver Cirrhosis.魚嶋 晴紀 (2019年10月 International Liver Conference 2019 一般演題(口演) 大阪)
  16. 抗GPIIb/IIIa抗体産生B細胞数がトロンボポエチン受容体アゴニスト投与後の治療効果に与 える影響 魚嶋 晴紀 第26回日本門脈圧亢進症学会(第8回脾臓研究会) (合同シンポジウム)
  17. 肝硬変患者におけるL-FABPより検討した腹水の有用性 魚嶋 晴紀 第26回日本門脈圧亢進症学会(第21回肝不全治療研究会) (合同シンポジウム)
  18. サルコペニアに対するレンバチニブ導入時の栄養療法の必要性 魚嶋 晴紀 第26回日本門脈圧亢進症学会 (ワークショップ)
  19. 肝線維化進展におけるAutotaxinの特徴に関する検討 魚嶋 晴紀 第26回日本門脈圧亢進症学会 (パネルディスカッション)
  20. 抗GPIIb/IIIa抗体産生B細胞数がトロンボポエチン受容体アゴニスト投与後の治療効果に与 える影響  魚嶋 晴紀 第26回日本門脈圧亢進症学会(第8回脾臓研究会) (合同シンポジウム)
  21. 肝性脳症に対するリファキシミン+カルニチン併用の意義 魚嶋 晴紀 田中 賢明 和田 尚久 窪田 幸介 日髙 央 岩崎 秀一郎 第55回日本肝臓学会総会(パネルディスカッション)
  22. 代償性肝硬変における筋肉量減少に関する検討 魚嶋 晴紀(2018年12月 第42回日本肝臓学会東部会 (パネルディスカッション)
  23. 慢性肝疾患に伴う血小板減少症に対する,トロンボポエチン受容体アゴニスト投与後の変化に関する前向き多施設共同研究 魚嶋 晴紀 日高 央  賀古 眞(2018年11月 第26回日本消化器関連学会週間(JDDW 2018) (ワークショップ)
  24. 肝性腹水合併肝硬変患者において、トルバプタン投与後の尿中ナトリウム排泄量の変化. 魚嶋晴紀. 第25回日本門脈圧亢進症学会総会 (ワークショップ)
  25. 脾腫が与えるルストロンボパグ投与後の血小板増加に関する検討. 魚嶋晴紀. 第25回日本門脈圧亢進症学会総会 (シンポジウム)
  26. 肝性脳症に対するレボカルニチン + リファキシミン併用療法の有用性.魚嶋晴紀. 第20回肝不全治療研究会 (合同シンポジウム)
  27. 肝性浮腫患者に対する水・ナトリウム利尿剤併用療法に関する前向き検討:arandomised pilotstudy.魚嶋晴紀, 日高央, 賀古眞.第54回日本肝臓学会 (パネルディスカッション)
  28. 門脈圧亢進症に伴う脾腫が与えるルストロンボパク投与後の血小板増加に関する検討.和田尚久, 魚嶋晴紀, 日高央. 第54回日本肝臓学会 (ワークショップ)
  29. Wisteria floribunda agglutinin-positive human Mac-2 binding protein in decompensated cirrhosis.魚嶋 晴紀(2018年5月 APASL 2018 The asian pacific association for the study of the liver. single topic conference on HCC 横浜)
  30. The asian pacific association for the study of the liver. single topic conference on HCC.魚嶋 晴紀(2018年5月 APASL STC 2018 横浜)
  31. 肝性浮腫患者に対する利尿剤投与後のeGFR変化に関する比較検討 魚嶋 晴紀 日高 央 金原 猛. 第25回日本消化器関連学会週間(JDDW 2017)(ワークショップ)
  32. トルバプタンResponder/Non-responderに対する治療戦略 魚嶋 晴紀.第24回日本門脈圧亢進症学会 (合同シンポジウム)
  33. 当院における門脈圧亢進症に伴う血小板減少症に対するルストロンボパクの使用経験 魚嶋 晴紀. 第24回日本門脈圧亢進症学会 (シンポジウム)
  34. 慢性肝疾患に伴う血小板減少症に対するルストロンボパクの使用経験. 魚嶋晴紀, 金原猛, 日高央. 第103回日本消化器病学会総会 (パネルディスカッション)
  35. Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascites.魚嶋 晴紀(2016年11月 APDW2016 神戸 oral)
  36. 腹水合併非代償性肝硬変におけるトルバプタン投与後の尿中ナトリウム排泄量と自由水クリアランスの変化. 魚嶋晴紀.第23回日本門脈圧亢進症学会 (合同シンポジウム)
  37. 腹水合併症非代償性肝硬変に対するトルバプタン併用療法のランダム化比較試験. 魚嶋 晴紀. 第52回日本肝臓学会(パネルディスカッション)
  38. 門脈圧亢進症の病態と課題 肝性浮腫に対するトルバプタンの治療効果.魚嶋晴紀,  金原猛, 賀古眞. 第101回日本消化器病学会総会(シンポジウム)
  39. 80歳以上の高齢者に対する腹部救急疾患の治療 80歳以上の高齢者における緊急内視鏡検査 魚嶋 晴紀, 伊藤亮二, 佐々木亜希子, 賀古眞. 第51回日本腹部救急医学会総会 (パネルディスカッション)
  40. 門脈圧亢進症の対策 門脈閉塞合併肝細胞癌に伴う肝性浮腫患者に対するトルバプタンの効果. 魚嶋 晴紀, 増田作栄, 金原猛.第40回肝臓学会東部会(ワークショップ)
  41. 高齢者の消化管出血とその有効な対策 高齢者における上部消化管出血時の抗血栓薬中止による治療経過への影響. 魚嶋晴紀, 江頭秀人, 賀古眞.第22回日本消化器関連学会週間(パネルディスカッション)
  42. 難治性胸・腹水の治療 肝性浮腫に対するトルバプタンの効果. 魚嶋晴紀, 金原猛, 賀古眞, 岩渕省吾. 第21回門脈圧亢進症学会 (パネルディスカッション)
  43. 高齢者の消化管出血 須田倫之, 魚嶋晴紀, 所晋之助. 第111回 日本内科学会総会・講演会 (サテライトシンポジウム)
  44. 魚嶋 晴紀 日高 央 アルコール性肝障害に対するHarm reduction導入後のdrinking risk levelの変化と治療効果に関する検討 第57回日本肝臓学会総会(ワークショップ)

 

【書籍】

  1. 柴田 実, 加藤 直也, 魚嶋 晴紀.消化器・肝臓内科vol2 No5 Nov.2017門脈圧亢進症の薬物p534~p537
  2. 肝疾患レジデントマニュアル 第3版.医学書院,2017
  3. 日高 央, 魚嶋 晴紀, 國分 茂博.門脈圧亢進症に対する内視鏡的治療 日本消化器病学会雑誌 116, 5号, 395-403, 2019
  4. 柴田 実, 加藤 直也, 魚嶋 晴紀.門脈圧亢進症の薬物.消化器・肝臓内科 2,No5,534-541,2017
  5. 柴田 実, 加藤 直也, 魚嶋 晴紀(共著).肝疾患レジデントマニュアル【第3版】.医学書院,2017
  6. 門脈圧亢進症の診療ガイドライン 文光堂
  7. 門脈圧亢進症取り扱い規約(第4版) 文光堂

【和文誌】

  1. 魚嶋 晴紀 骨格筋量と有害事象の関連とレンバチニブ治療の工夫 クリニシアン(エーザイ製薬㈱発行/北里大学のみ所属記載) 65巻10号31 2020
  2. 魚嶋 晴紀 田中 賢明 日高 央 四栁 宏 HIV感染患者に発生した急性A型肝炎の1例 臨床消化器内科 Vol.34,No12,1519-1523,2019
  3. 日高 央  魚嶋 晴紀 國分 茂博(湘鎌記載なし)門脈圧亢進症に対する内視鏡的治療 日本消化器病学会雑誌 116, 5号, 395-403, 2019
  4. 柴田 実, 加藤 直也, 魚嶋 晴紀 門脈圧亢進症の薬物.消化器・肝臓内科 Vol.2,No5,534-541,2017
  5. 柴田 実 加藤 直也 魚嶋 晴紀(共著)肝疾患レジデントマニュアル【第3版】医学書院,2017
  6. 魚嶋 晴紀  賀古 眞 肝性浮腫に対するトルバプタンの利尿効果と安全性.日本門脈圧更新症学会雑誌22, 152-158,2016
  7. 魚嶋 晴紀  伊藤 亮治  賀古 眞 急性A型肝炎を契機にacute on chronic型肝不全に陥った高齢常習飲酒家の1例 日本腹部救急医学会雑誌 第34巻, 1537-1540,2014
  8. 魚嶋 晴紀  小泉 一也  山本 章太  市田 親正  所 晋之助  増田 作栄  佐々木 亜希子  江頭 秀人  金原 猛  賀古 眞 経胃的ドレナージ術が奏功した胃穿通化膿性肝膿瘍の1例 日本消化器内視鏡学会雑誌 No.56,3798-3804,2014
  9. 魚嶋 晴紀  築山 俊毅  市田 親正  土屋 貴愛  糸井 隆夫 n-butyl-2-cyanoacrylate使用下動脈塞栓術が有効であった膵動静脈奇形の1例 日本消化器病学会雑誌 111,2174-2180,2014
  10. 魚嶋 晴紀  伊藤 亮治  加藤 一郎  賀古 眞 外発性肝嚢胞の外傷性破裂に伴う嚢胞液の胸腔内流入と肝嚢胞感染を合併した1例 日本腹部救急医学会雑誌.31, 153-156,2014
  11. 魚嶋 晴紀  所 晋之助  増田 作栄  冨嶋 享  佐々木亜希子  金原 猛 賀古 眞 ガス産生の有無で異なる経過をたどった化膿性肝膿瘍破裂の2例.日本消化器病学会雑誌12, 2136-2141,2013.

【受賞】

第20回(2022年度)森村豊明会奨励賞

【科研費】

24K11093   基金2024年度 基盤研究(C)                                                                                アルコール性肝障害に伴う血小板減少に関する抗血小板抗体の病因的意義の解明    

2023年度 若手研究 口腔細菌による肝性脳症の増悪メカニズムの解明

【研究助成】

第34回(2022年度)SGHがん研究助成

【症例・臨床治験報告】

  1. 魚嶋 晴紀  伊藤 亮治  賀古 眞:急性A型肝炎を契機にacute on chronic型肝不全に陥った高齢常習飲酒家の1例 日本腹部救急医学会雑誌、34:1537~1540,2014.
  2. 魚嶋 晴紀  小泉 一也  山本 章太  市田 親正  所 晋之助 増田 作栄  佐々木亜希子  江頭 秀人 金原 猛  賀古 眞 経胃的ドレナージ術が奏功した胃穿通化膿性肝膿瘍の1例.Gastroenterological Endoscopy、56:3798~3804,2014.
  3. 魚嶋 晴紀  築山 俊毅  市田 親正  土屋 貴愛  糸井 隆夫:n-butyl-2-cyanoacrylate使用下動脈塞栓術が有効であった膵動静脈奇形の1例 日本消化器病学会雑誌 111,2174-2180,2014.
  4. 魚嶋 晴紀  伊藤 亮治  加藤 一郎  賀古 眞 外発性肝嚢胞の外傷性破裂に伴う嚢胞液の胸腔内流入と肝嚢胞感染を合併した1例 日本腹部救急医学会雑誌、31:153~156,2014.
  5. 魚嶋 晴紀  所 晋之助  増田 作栄  冨嶋 享 佐々木 亜希子  金原 猛  賀古 眞:ガス産生の有無で異なる経過をたどった化膿性肝膿瘍破裂の2例 日本消化器病学会雑、12:2136~2141,2013.
  6. Koizumi K, Masuda S, Uojima H, Ichita C, Tokoro S, Sasaki A, Egashira H, Kimbara T, Kako M. Endoscopic ultrasound-guided drainage of an amoebic liver abscess extending into the hepatic subcapsular space. Clin J Gastroenterol. 2015 Aug;8(4):232-5. doi: 10.1007/s12328-015-0585-8. Epub 2015 Jul 24. PMID: 26204883
  7. Sasaki A, Nakajima T, Egashira H, Takeda K, Tokoro S, Ichita C, Masuda S, Uojima H, Koizumi K, Kinbara T, Sakamoto T, Saito Y, Kako M. Condyloma acuminatum of the anal canal, treated with endoscopic submucosal dissection. World J Gastroenterol. 2016 Feb 28;22(8):2636-41. doi: 10.3748/wjg.v22.i8.2636. PMID: 26937152
  8. Hyun Sung J, Uojima H, Branch J, Miyazono S, Kitagawa I, Kako M, Kobayashi S.Platypnea-orthodeoxia Syndrome Induced by an Infected Giant Hepatic Cyst. Intern Med. 2017;56(15):2019-2024. doi: 10.2169/internalmedicine.56.8004. Epub 2017 Aug 1. PMID: 28768974
  9. Uojima H, Murakami S, Nakatani S, Hidaka H, Takeuchi A, Tanaka Y, Inoue T, Yamane K, Kubota K, Nakazawa T, Shibuya A, Tanaka Y, Koizumi W. Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis. Intern Med. 2018 Apr 1;57(7):951-956. doi: 10.2169/internalmedicine.9671-17. Epub 2017 Dec 8. PMID: 29225269
  10. Ono R, Kumagae T, Uojima H, Teshima S, Kudo M, Kitagawa I, Yoshizawa M. Hepatic methotrexate-associated lymphoproliferative disorders identified by multiple liver tumors: a case report and review of the literature. J Med Case Rep. 2019 Jun 27;13(1):196. doi: 10.1186/s13256-019-2135-3. PMID: 31242930
  11. Masuda S, Koizumi K, Uojima H, Tazawa T, Tasaki J, Ichita C, Nishino T, Kimura K, Sasaki A, Egashira H, Kako M. Ischemic pancreatitis with infected walled-off necrosis with a colonic fistula after cardiopulmonary bypass successfully treated by endoscopic ultrasound-guided drainage. Clin J Gastroenterol. 2020 Feb;13(1):127-133. doi: 10.1007/s12328-019-01019-0. Epub 2019 Jul 20.
  12. Masuda S, Koizumi K, Uojima H, Tazawa T, Kimura K, Nishino T, Tasaki J, Ichita C, Sasaki A, Egashira H, Kako M. Pancreatic pseudocyst-portal vein fistula: a case treated with EUS-guided cyst-drainage and a review of the literature. Clin J Gastroenterol. 2020 Mar 25. doi: 10.1007/s12328-020-01105-8. Online ahead of print. PMID: 32215857
  13. Manabe Y, Uojima H, Hidaka H, Shao X, Iwasaki S, Wada N, Kubota K, Tanaka Y, Nakazawa T, Shibuya A, Masaaki I, Kumamoto Y, Kaizu T, Koizumi W. Undifferentiated Embryonal Sarcoma of the Liver Identified after the Initial Diagnosis of a Hepatic Cyst: A Case Report. Intern Med. 2020 Jun 30. doi: 10.2169/internalmedicine.4853-20. Online ahead of print. PMID: 32611966
  14. 魚嶋 晴紀  田中 賢明  日高 央  四栁 宏 HIV感染患者に発生した急性A型肝炎の1例.臨床消化器内科 Vol.34,No12,1519-1523,2019

 

現在の研究テーマ

  • 「ミリプラチンを使用したマイクロバルーン閉塞下選択的肝動脈化学塞栓術の肝細胞癌に対する有用性の検討」
  • 「肝硬変患者に対する肝不全用経口栄養剤投与後の筋力/骨格筋量の変化の検討」
  • 「血液透析患者における難治性C型慢性肝炎に対するアスナプレビル+ダクラタスビル2剤併用療法導入の検討」
  • 「BCAA顆粒製剤リーバクトの就寝前投与における肝硬変病態改善効果に関する検討」
  • 「肝性浮腫患者におけるトルバプタンの有効性の検討」

 

コメント

日頃より経験できる日常診療から世界に通用する論文作成を目標とします。